Business, energy, technology, markets and global industry news from Business News Today

ALK-positive non-small cell lung cancer

PharmaDeviceNews ALK-positive non-small cell lung cancer
Representative image of an oncologist reviewing lung cancer scans with a patient, reflecting Nuvalent’s neladalkib FDA Priority Review and the growing race to develop targeted therapies for ALK-positive non-small cell lung cancer.
Pharma & Biotech

Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves

Nuvalent’s neladalkib has FDA Priority Review in ALK-positive lung cancer. Find out why resistance and brain metastases drive the story.

Read More